Rintatolimod

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

Retrieved on: 
星期一, 五月 6, 2024
CGMP, Rintatolimod, Immune system, AIM, Clinical trial, Cancer, Viral

OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen ® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.

Key Points: 
  • OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen ® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
  • AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies.
  • This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success.
  • Ampligen has had a series of clinical trial advances in 2024.

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Retrieved on: 
星期四, 四月 25, 2024
Rintatolimod, AIM

OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website.

Key Points: 
  • OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website.
  • For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, gave an overview of Metastatic Pancreatic Cancer and the ongoing Phase 1b/2 clinical trial combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer (the “DURIPANC Study”).

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期二, 四月 2, 2024
Research, Conference, Rintatolimod, Webcast, Cancer, Doctor of Philosophy, Investment, Event, Patent, Fatigue, AIM, Cryptocurrency

OCALA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the full year 2023 and provided a business update. As previously announced, the Company will host a conference call and webcast today, Tuesday, April 2, 2024, at 8:30 AM ET (details below).

Key Points: 
  • Company to host conference call and webcast today, April 2nd at 8:30 AM ET
    OCALA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the full year 2023 and provided a business update.
  • As previously announced, the Company will host a conference call and webcast today, Tuesday, April 2, 2024, at 8:30 AM ET (details below).
  • “AIM reported positive data across many fronts in 2023 and the first quarter of 2024.
  • Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call.

AIM ImmunoTech Announces Launch of CEO Corner Platform

Retrieved on: 
星期四, 三月 7, 2024
Corner, AIM ImmunoTech, AIM, Rintatolimod, Management

OCALA, Fla., March 07, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the launch of its CEO Corner featuring Thomas K Equels, M.S., J.D., Executive Vice Chairman, Chief Executive Officer & President of AIM ImmunoTech. The CEO Corner platform is intended to provide additional and in-depth perspective to press releases, corporate developments and development pipeline progress.

Key Points: 
  • CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress
    Access the AIM CEO Corner Here!
  • OCALA, Fla., March 07, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the launch of its CEO Corner featuring Thomas K Equels, M.S., J.D., Executive Vice Chairman, Chief Executive Officer & President of AIM ImmunoTech.
  • The CEO Corner platform is intended to provide additional and in-depth perspective to press releases, corporate developments and development pipeline progress.
  • “CEO Corner is a new way for us to connect directly with both current and potential stockholders.

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

Retrieved on: 
星期四, 二月 29, 2024
AIM, Ovarian cancer, Patent, Rintatolimod, Pancreatic cancer, Cancer, Partnership, Pharmaceutical industry

OCALA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent accomplishments and provided a business outlook. AIM’s dsRNA product candidate, Ampligen® (rintatolimod), is being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at major cancer research centers around the country.

Key Points: 
  • OCALA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent accomplishments and provided a business outlook.
  • AIM’s dsRNA product candidate, Ampligen® (rintatolimod), is being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at major cancer research centers around the country.
  • In addition to its ongoing clinical and business development activities, the Company will continue to engage with the industry and investment communities by actively participating in meetings, virtual events and key conferences over the course of the year.
  • To stay up to date with the Company’s activities visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .

PRISM MarketView Marks World Cancer Day

Retrieved on: 
星期四, 二月 1, 2024
CONNECT, Melanoma, GBM, AIM, University, Breast, Prostate cancer, Acute myeloid leukemia, Renal cell carcinoma, Research, Prostate, Pancreatic cancer, Janssen Pharmaceuticals, Therapy, Patient, AML, ASCO, Temozolomide, PRISM, MD Anderson Cancer Center, FDA, Glioblastoma, Death, Rintatolimod, Glioma, Cancer, Olutasidenib, Pharmaceutical industry

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.

Key Points: 
  • NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.
  • To mark World Cancer Day , which will be held on February 4, PRISM MarketView highlights emerging companies working to improve the lives of cancer patients and their families by developing and commercializing innovative new treatments for cancer.
  • The company has entered a research agreement with the Johns Hopkins University School of Medicine for the development of Ivospemin.
  • Essa Pharma, a clinical stage pharmaceutical company, is focused on the development of small molecule drugs for the treatment of prostate cancer.

AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents

Retrieved on: 
星期二, 十一月 28, 2023
CDC, Research, Pain, Colorectal cancer, Mortality, Renal cell carcinoma, Chronic fatigue syndrome, Fatigue, Patent, Exercise, Melanoma, AIM, Myalgia, Rintatolimod, ME/CFS, Pancreatic cancer, Cancer, Public, Patient, Medicine, United States patent law, Pharmaceutical industry

OCALA, Fla., Nov. 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 11,813,279 and 11,813,281 for Ampligen® titled “Compositions for cancer therapy and methods,” and “Methods for improving exercise tolerance in myalgic encephalomyelitis patients,” respectively.

Key Points: 
  • 11,813,279 and 11,813,281 for Ampligen® titled “Compositions for cancer therapy and methods,” and “Methods for improving exercise tolerance in myalgic encephalomyelitis patients,” respectively.
  • AIM Chief Executive Officer Thomas K. Equels stated: “Our ongoing effort to expand and solidify AIM’s global intellectual property estate is a foundational component of our development strategy for Ampligen.
  • The combination of these compounds is designed to work synergistically to enhance the effectiveness of the treatment.
  • This exclusivity fortifies AIM's position in the market by enabling development of a distinctive and unparalleled treatment option.

AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents

Retrieved on: 
星期一, 十一月 27, 2023
CDC, Research, Pain, Colorectal cancer, Mortality, Renal cell carcinoma, Chronic fatigue syndrome, Fatigue, Patent, Exercise, Melanoma, AIM, Myalgia, Rintatolimod, ME/CFS, Pancreatic cancer, Cancer, Public, Patient, Medicine, United States patent law, Pharmaceutical industry

OCALA, Fla., Nov. 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 11,813,279 and 11,813,281 for Ampligen® titled “Compositions for cancer therapy and methods,” and “Methods for improving exercise tolerance in myalgic encephalomyelitis patients,” respectively.

Key Points: 
  • 11,813,279 and 11,813,281 for Ampligen® titled “Compositions for cancer therapy and methods,” and “Methods for improving exercise tolerance in myalgic encephalomyelitis patients,” respectively.
  • AIM Chief Executive Officer Thomas K. Equels stated: “Our ongoing effort to expand and solidify AIM’s global intellectual property estate is a foundational component of our development strategy for Ampligen.
  • The combination of these compounds is designed to work synergistically to enhance the effectiveness of the treatment.
  • This exclusivity fortifies AIM's position in the market by enabling development of a distinctive and unparalleled treatment option.

AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update

Retrieved on: 
星期三, 十一月 15, 2023
Webcast, AIM, Pancreatic cancer, NYSE, Rintatolimod, Investment, Patient, Research, CKM, Event, Conference, Ovarian cancer, Doctor of Philosophy, TNBC, Pharmaceutical industry, Cryptocurrency

OCALA, Fla., Nov. 15, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the third quarter 2023 and provided a business update. As previously announced, the Company will host a conference call and webcast today, Wednesday, November 15, 2023, at 8:30 AM ET (details below).

Key Points: 
  • – Will host conference call and webcast today, November 15th at 8:30 AM ET
    OCALA, Fla., Nov. 15, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the third quarter 2023 and provided a business update.
  • As previously announced, the Company will host a conference call and webcast today, Wednesday, November 15, 2023, at 8:30 AM ET (details below).
  • We are dedicated to driving our clinical programs forward and building momentum to generate value for our shareholders,” commented Thomas K. Equels, Chief Executive Officer of AIM.
  • As of September 30, 2023, AIM reported cash, cash equivalents and marketable investments of $22.4 million.

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer

Retrieved on: 
星期二, 十一月 14, 2023
CTL, AIM, Safety, NYSE, Senior, Breast cancer, Celecoxib, Roswell Park, Rintatolimod, Paper, Patient, TLR3, Journal, Immunology, CKM, Pembrolizumab, AIM ImmunoTech, Science of team science, Immunotherapy, Doctor of Philosophy, Manuscript, Pharmaceutical industry, Management, Cancer, MD

OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed by pembrolizumab.

Key Points: 
  • OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed by pembrolizumab.
  • The data were published in a manuscript titled, “ Systemic Infusion of TLR3-Ligand and IFNα in Breast Cancer Patients Reprograms Local Tumor Microenvironment for Selective CTL Influx ,” in The Journal for ImmunoTherapy of Cancer.
  • The pilot study evaluated the safety of systemic CKM composed of intravenous rintatolimod (Ampligen; selective TLR3 ligand), interferon α-2b and celecoxib, and the combination’s ability to promote local CTL influx to mTNBC lesions.
  • For more information about the study, please visit ClinicalTrials.gov: NCT03599453 .